Modified Lipids for Nucleic Acid Encapsulation and Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid nanoparticle compositions for nucleic acid delivery face challenges in safety, efficacy, and specificity, particularly due to instability, low permeability, and unwanted activation of the innate immune response.
Innovation Solution
Development of modified lipids, including cationic or ionizable lipid conjugates with amino acids or IDO inhibitors, for use in liposomal and lipid nanoparticle delivery systems to enhance encapsulation and delivery efficiency, promoting macrophage polarization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid nanoparticle compositions are used for nucleic acid delivery, then delivery capability is achieved, but stability and safety are compromised due to instability, low permeability, and unwanted immune activation
Solution Approach 1:
The patent modifies the chemical structure of lipids by changing parameters such as chain length (C16-C30), degree of unsaturation, and head group composition to create ionizable lipids with optimized properties. These parameter changes improve delivery stability while reducing immune activation compared to conventional lipids
Solution Approach 2:
The patent creates composite lipid structures by combining ionizable lipid head groups with specific hydrocarbon chains and functional groups. These composite materials exhibit improved stability and reduced harmful immune effects while maintaining delivery capability
2Productivity
If cationic or ionizable lipids are used to encapsulate nucleic acid, then transfection efficiency is improved, but safety and specificity remain insufficient
Solution Approach 1:
The patent introduces specific functional groups at localized positions within the lipid structure (e.g., ionizable groups at the head, specific chain compositions) to create regions with different properties. This local quality optimization enables high transfection efficiency in the head region while maintaining safety through controlled charge distribution
Solution Approach 2:
The ionizable lipids exhibit dynamic charge properties that change with pH environment. The lipids remain neutral in circulation (improving safety) but become positively charged in endosomal environments (enhancing transfection efficiency), thus resolving the contradiction between safety and productivity
3Quantity of substance
If lipid nanoparticle compositions are designed for nucleic acid delivery, then encapsulation is achieved, but permeability and delivery efficiency remain low
Solution Approach 1:
The patent optimizes the three-dimensional structure of lipid nanoparticles by controlling size distribution, surface charge density, and internal organization. These dimensional optimizations enable efficient nucleic acid encapsulation while improving cellular uptake and delivery efficiency through size-dependent endocytosis pathways
Data Source
AI summary
The present disclosure provides compounds, compositions, formulations, and methods for delivery of active agents (e.g., nucleic acid). In particular, the present disclosure provides modified lipids (e.g., lipids conjugated with 1-methyl-D-tryptophan) for use in delivery of active agents and compositions and vaccines thereof.